{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:34:31Z","timestamp":1790937271247,"version":"4.1.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1097\/fpc.0b013e32835a5af2","type":"journal-article","created":{"date-parts":[[2012,10,26]],"date-time":"2012-10-26T07:20:21Z","timestamp":1351236021000},"page":"868-876","source":"Crossref","is-referenced-by-count":31,"title":["Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians"],"prefix":"10.1097","volume":"22","author":[{"given":"Julie","family":"Bertrand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monidarin","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle M.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Verstuyft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Leger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"France","family":"Mentr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Taburet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210213","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1097\/01.aids.0000226957.79847.d6","article-title":"Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort.","volume":"20","author":"Calmy","year":"2006","journal-title":"AIDS"},{"key":"R2-5-20210213","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(04)16586-0","article-title":"Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial.","volume":"364","author":"Laurent","year":"2004","journal-title":"Lancet"},{"key":"R3-5-20210213","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0090-9556(24)15239-7","article-title":"Disposition and biotransformation of the antiretroviral drug nevirapine in humans.","volume":"27","author":"Riska","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"R4-5-20210213","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/S0090-9556(24)14960-4","article-title":"Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450.","volume":"27","author":"Erickson","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"R5-5-20210213","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1124\/dmd.108.024851","article-title":"Metabolic activation of nevirapine in human liver microsomes: dehydrogenation and inactivation of cytochrome P450 3A4.","volume":"37","author":"Wen","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"R6-5-20210213","doi-asserted-by":"crossref","first-page":"598","DOI":"10.2174\/138920008785821710","article-title":"CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme.","volume":"9","author":"Wang","year":"2008","journal-title":"Curr Drug Metab"},{"key":"R7-5-20210213","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.clpt.2005.04.004","article-title":"Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals.","volume":"78","author":"Almond","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R8-5-20210213","doi-asserted-by":"crossref","first-page":"276","DOI":"10.2133\/dmpk.22.276","article-title":"Broad but distinct role of pregnane X receptor on the expression of individual cytochrome p450s in human hepatocytes.","volume":"22","author":"Kojima","year":"2007","journal-title":"Drug Metab Pharmacokinet"},{"key":"R9-5-20210213","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects: an adult AIDS Clinical Trials Group study.","volume":"18","author":"Haas","year":"2004","journal-title":"AIDS"},{"key":"R10-5-20210213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01213011-200501000-00001","article-title":"Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients.","volume":"15","author":"Rotger","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"R11-5-20210213","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/jac\/dkn029","article-title":"Impact of CYP2B6 983TC polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.","volume":"61","author":"Wyen","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"R12-5-20210213","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1468-1293.2008.00689.x","article-title":"Cytochrome P450 2B6 516GT is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population.","volume":"10","author":"Mahungu","year":"2009","journal-title":"HIV Med"},{"key":"R13-5-20210213","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1468-1293.2007.00432.x","article-title":"Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda.","volume":"8","author":"Penzak","year":"2007","journal-title":"HIV Med"},{"key":"R14-5-20210213","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1097\/QAD.0b013e3282ef9695","article-title":"CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.","volume":"21","author":"Saitoh","year":"2007","journal-title":"AIDS"},{"key":"R15-5-20210213","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/jac\/dkp033","article-title":"Association of high T allele frequency of CYP2B6 G516T polymorphism among ethnic south Indian HIV-infected patients with elevated plasma efavirenz and nevirapine.","volume":"63","author":"Ramachandran","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"R16-5-20210213","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1742-6405-7-8","article-title":"Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIVTB co-infected Thai adults.","volume":"7","author":"Uttayamakul","year":"2010","journal-title":"AIDS Res Ther"},{"key":"R17-5-20210213","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1086\/597125","article-title":"Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African Americans.","volume":"199","author":"Haas","year":"2009","journal-title":"J Infect Dis"},{"key":"R18-5-20210213","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1093\/jac\/dkp351","article-title":"Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women.","volume":"64","author":"Chantarangsu","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"R19-5-20210213","doi-asserted-by":"crossref","first-page":"4432","DOI":"10.1128\/AAC.00512-10","article-title":"Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients.","volume":"54","author":"Chou","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R21-5-20210213","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/sj.clpt.6100072","article-title":"Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.","volume":"81","author":"Rotger","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R23-5-20210213","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1124\/jpet.103.054866","article-title":"Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR expression.","volume":"307","author":"Lamba","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"R25-5-20210213","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/bioinformatics\/bth457","article-title":"Haploview: analysis and visualization of LD and haplotype maps.","volume":"21","author":"Barrett","year":"2005","journal-title":"Bioinformatics"},{"key":"R26-5-20210213","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1086\/519795","article-title":"PLINK: a tool set for whole-genome association and population-based linkage analyses.","volume":"81","author":"Purcell","year":"2007","journal-title":"Am J Hum Genet"},{"key":"R27-5-20210213","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/01.qai.0000225020.73760.c2","article-title":"Visual analog scale of ART adherence: association with 3-day self-report and adherence barriers.","volume":"42","author":"Amico","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R29-5-20210213","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/00008571-200310000-00005","article-title":"Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.","volume":"13","author":"Kirchheiner","year":"2003","journal-title":"Pharmacogenetics"},{"key":"R30-5-20210213","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/FPC.0b013e32834a522e","article-title":"Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine.","volume":"21","author":"Lehr","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"R32-5-20210213","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/tpj.2010.28","article-title":"Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs.","volume":"11","author":"Wang","year":"2011","journal-title":"Pharmacogenom J"},{"key":"R33-5-20210213","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1373\/clinchem.2011.165613","article-title":"A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.","volume":"57","author":"Elens","year":"2011","journal-title":"Clin Chem"},{"key":"R34-5-20210213","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/01.fpc.0000189797.03845.90","article-title":"Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz.","volume":"16","author":"Wang","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"R35-5-20210213","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/655470","article-title":"Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.","volume":"202","author":"Ribaudo","year":"2010","journal-title":"J Infect Dis"},{"key":"R36-5-20210213","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/FTD.0b013e31824868f3","article-title":"Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals.","volume":"34","author":"Heil","year":"2012","journal-title":"Ther Drug Monit"},{"key":"R37-5-20210213","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/FPC.0b013e32831d0faf","article-title":"HLA-B3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients.","volume":"19","author":"Chantarangsu","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"R38-5-20210213","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1742-6405-6-22","article-title":"HLA-Cw04 allele associated with nevirapine-induced rash in HIV-infected Thai patients.","volume":"6","author":"Likanonsakul","year":"2009","journal-title":"AIDS Res Ther"},{"key":"R39-5-20210213","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00002030-200501030-00014","article-title":"Predisposition to nevirapine hypersensitivity associated with HLA-DRB10101 and abrogated by low CD4 T-cell counts.","volume":"19","author":"Martin","year":"2005","journal-title":"AIDS"},{"key":"R40-5-20210213","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1097\/QAD.0b013e32834779df","article-title":"Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent.","volume":"25","author":"Yuan","year":"2011","journal-title":"AIDS"},{"key":"R41-5-20210213","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/QAD.0b013e328351a521","article-title":"Nevirapine (NVP) pharmacokinetics (PK) and risk of rash and hepatitis among HIV-infected Sub-Saharan African Women.","volume":"26","author":"Dong","year":"2012","journal-title":"AIDS"},{"key":"R42-5-20210213","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1093\/jac\/dkr087","article-title":"Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.","volume":"66","author":"Schipani","year":"2011","journal-title":"J Antimicrob Chemother"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/01213011-201212000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T18:18:54Z","timestamp":1745086734000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201212000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0b013e32835a5af2","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}